Fortress Biotech Inc. (FBIO)
1.89
-0.08 (-3.82%)
At close: Jan 14, 2025, 3:59 PM
1.88
-0.53%
Pre-market Jan 15, 2025, 05:10 AM EST
undefined% (undefined)
| Bid | 1.86 |
| Market Cap | 52.17M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.96 |
| PE Ratio (ttm) | -0.64 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 2.35 |
| Volume | 433,610 |
| Avg. Volume (20D) | 662,567 |
| Open | 1.92 |
| Previous Close | 1.97 |
| Day's Range | 1.86 - 1.95 |
| 52-Week Range | 1.36 - 2.89 |
| Beta | undefined |
About FBIO
Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 17, 2011
Employees 186
Stock Exchange NASDAQ
Ticker Symbol FBIO
Website https://www.fortressbiotech.com
Analyst Forecast
According to 3 analyst ratings, the average rating for FBIO stock is "Buy." The 12-month stock price forecast is $18, which is an increase of 852.38% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Fortress Biotech Inc. is scheduled to release its earnings on Mar 27, 2025,
during market hours.
Analysts project revenue of $15.58M, reflecting a -21.89% YoY shrinking and earnings per share of -0.75, making a 41.51% increase YoY.
Analysts project revenue of $15.58M, reflecting a -21.89% YoY shrinking and earnings per share of -0.75, making a 41.51% increase YoY.
3 months ago ·
Source
-18.48%
Fortress Biotech shares are trading lower after th...
Unlock content with
Pro Subscription
6 months ago ·
Source
Fortress Biotech shares are trading lower after the company announced a pause in the payment of dividends on its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock.
